The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Michael Wick
Employment - The START Center for Cancer Care
Leadership - The START Center for Cancer Care
Stock and Other Ownership Interests - The START Center for Cancer Care
 
Alyssa Moriarty
No Relationships to Disclose
 
Anna Stackpole
No Relationships to Disclose
 
Peter Forofontov
No Relationships to Disclose
 
Jennifer Garcia
No Relationships to Disclose
 
Jim Lund
Research Funding - XenoSTART
 
Ian Sturgill
Employment - The Permanente Medical Group (I)
Stock and Other Ownership Interests - Arcturus Therapeutics; UnitedHealthcare
 
Guillermo Sanz Martin
Employment - START – The START Center for Cancer Research
 
Naveen Kella
Employment - The Urology Place
Consulting or Advisory Role - Profound Medical
Speakers' Bureau - Telix Pharmaceuticals
 
Nehal Lakhani
Consulting or Advisory Role - Janssen Oncology
Research Funding - Adcentrx (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Biosplice (Inst); Bright Peak Therapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Celgene (Inst); Circle Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Day One Biopharmaceuticals (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Treeline Biosciences (Inst); Treeline Biosciences (Inst); Treeline Biosciences (Inst)
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Pfizer; Regeneron; Vertex
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Pliant; Whitehawk Therapeutics
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Arcus Biosciences (Inst); Artios (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Circle Pharma (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); Debiopharm Group (Inst); Deciphera (Inst); EvolveImmune Therapeutics (Inst); Exelixis (Inst); Exscientia (Inst); FoRx Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Halda Therapeutics (Inst); Helsinn Therapeutics (Inst); Iambic Therapeutics (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); KLUS Pharma (Inst); Kumquat Biosciences (Inst); Macrogenics (Inst); Mbrace Therapeutics (Inst); MediLink Therapeutics (Inst); Menarini Group (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mitsubishi Tanabe Pharma (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Olema Pharmaceuticals (Inst); Opna Bio (Inst); Pfizer (Inst); Pliant (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Third Arc Bio (Inst); Treeline Biosciences (Inst); VelaVigo Bio (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Chris Takimoto
Employment - IGM Biosciences; START Research
Leadership - ALX Oncology; IgM Biosciences; START
Stock and Other Ownership Interests - ALX Oncology; Gilead/Forty Seven; IGM Biosciences; Johnson & Johnson
Consulting or Advisory Role - Alphina; BioAtla; Bioconvergent; Expedition Therapeutics; Thetis Pharma; Tucerna
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Neal Shore
Stock and Other Ownership Interests - Photocure
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; ImmunityBio; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Nusano; Pfizer; Photocure; PlatformQ Health; Promaxo; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow